Syntermed anticipates NeuroQ approval

A software platform consisting of quantitative tools for the analysis of brain PET scans has just been submitted to the FDA, but its maker, Syntermed, is already looking forward to marketing the product. The company expects commercial release in the third quarter for the NeuroQ software, which rapidly and automatically quantifies more than 200 standardized regions of interest. It compares activity in those brain regions to regional activity values derived from a database of normal scans.